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Editorial
Serum Albumin Levels: A Simple Answer to a Complex 
Problem? Are We on the Right Track of Assessing 
Metabolic Syndrome?
Sohee Kim, Shinae Kang
Division of Endocrinology and Metabolism, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea
Serum albumin makes up a major portion of circulating pro-
teins in our body. Serum albumin level is closely linked to the 
body’s nutritional (malnutrition/overnutrition) and inflamma-
tory status. Insulin resistance is the main pathogenetic mecha-
nism underlying metabolic syndrome, a condition that is asso-
ciated with obesity and chronic vascular inflammation [1]. 
Several studies have focused on the association between se-
rum albumin level and factors/diseases related to metabolic 
syndrome (insulin resistance, diabetes, and cardiovascular dis-
ease).
 In this issue, Bae et al. [2] reported that a high serum albu-
min level is associated with insulin resistance, but they failed 
to show a significant correlation between serum albumin level 
and the development of diabetes in a longitudinal follow-up. 
The authors analyzed data for a large cohort from a health pro-
motion center located in an urban area, Seoul, South Korea. 
Cho et al. [3] also reported a positive relationship between se-
rum albumin level and metabolic syndrome, although they 
studied a healthy adult population located in a rural area.
 Bae et al. [2] explained that the positive association be-
tween serum albumin level and insulin resistance might be a 
consequence of increased albumin production in the liver un-
der insulin-resistant conditions. Insulin resistance goes hand-
in-hand with increased insulin levels and insulin is known to 
stimulate albumin production in hepatocytes [4]. On the other 
hand, some reports have shown that albumin has a cardiopro-
tective effect [5,6] that may be due to albumin acting as an an-
tioxidant and a protective protein against chronic inflamma-
tion [1,7]. Albumin is a main constituent of serum proteins and, 
owing to its presence in vast amounts, it accounts for approxi-
mately 80% of thiol’s antioxidant effect in the body [8]. The 
free 34cysteine (34Cys) residue of albumin reacts with reactive 
oxygen species, generating two reversible intermediate deriva-
tives, and finally sulfonic-albumin, which is susceptible to en-
zymatic digestion compared with the nonoxidized counter 
molecule [9]. Therefore, serum albumin seems to have com-
plicated effects on metabolic syndrome and related factors/
diseases.
 Several reports have shown a negative correlation between 
serum albumin level and cardiovascular risk factors, as well as 
cardiovascular disease [10,11]. However, there have also been 
conflicting reports that serum albumin level is not associated 
with atherosclerosis as evaluated by carotid imtima media 
thickness [12]. To make matters even more difficult to inter-
pret, there are also papers demonstrating positive relationships 
between serum albumin level and vascular dysfunction as 
measured by pulse wave velocity [6], as well as early carotid 
atherosclerosis [5]. These differences in findings between pa-
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pers demonstrate a possible complex mechanism that under-
lies the interaction between albumin’s antioxidant capacities. 
More specifically, the antioxidant effect of albumin is not 
solely dependent on the amount of serum albumin per se, but 
also on the oxidative status of albumin. Previous papers have 
demonstrated that the antioxidant capacity of albumin is de-
creased in various disease conditions, such as diabetes [13], 
and in patients on hemodialysis [14]. Furthermore, insulin sig-
naling is altered under insulin-resistant conditions and insulin 
levels decrease in the later stages of diabetes. Therefore, the 
answer may lie in the total antioxidant capacity of serum albu-
min and not the total amount of albumin itself. In this context, 
a plausible explanation of the findings by Bae et al. [2] in this 
issue of the journal would be that the increase in serum albu-
min level may be because of a compensatory increase in albu-
min production that is due to a decrease in the antioxidant ef-
fects of albumin in an insulin-resistant state.
 What, then, is the main message of the study by Bae et al. 
[2]? Serum albumin is relatively simple to measure and is in-
cluded in every admission panel throughout Korea. Testing is 
inexpensive and does not need fasting for proper measure-
ment, which certainly makes it more comfortable for patients 
visiting the hospital. Therefore, Bae et al. [2] are to be con-
gratulated for re-emphasizing the clinical utility of a simple 
biomarker in evaluating a patient’s complex metabolic status 
under stable metabolic conditions. Although the study fails to 
show a positive correlation between the development of diabe-
tes and serum albumin level, a larger population or a longer 
follow-up period may be all that is needed. The medical soci-
ety certainly awaits the results of such investigations.
 And what remains to be investigated? First, the findings 
urge a large-scale population analysis on whether albumin lev-
el in a healthy population may serve as a good surrogate mark-
er for future cardiovascular events. Because there are data in 
Western countries demonstrating that serum albumin level is 
associated with cardiovascular outcomes [10,15], a separate 
study in Asia, and particularly Korea, is definitely needed. 
This is important, especially considering that the pathogenetic 
mechanism leading to diabetes may be influenced by several 
factors, including genetic factors. Second, the total amount of 
albumin may not accurately reflect the total antioxidant capa-
bility, as discussed earlier. The data of Bae et al. [2] should 
also be supported by a thorough, mechanistic, in vitro analysis. 
Third, is the antioxidant property of albumin reversed with the 
improvement of a patient’s metabolic status? This remains a 
crucial step to providing a definite answer as to whether albu-
min is really a good marker.
 In conclusion, Bae et al. [2] have reinforced an important 
positive association between serum albumin level and param-
eters of insulin resistance in healthy Korean adults. In addi-
tion, even though they did not show a significant association 
between albumin level and diabetes development, the report is 
one of the first longitudinal studies to evaluate this issue. Fur-
ther investigations are needed to demonstrate whether albumin 
is indeed ‘the’ important antioxidant in the body and whether 
it is linked to clinical outcomes. The medical society awaits 
the answers to these questions. 
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